# Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

> **NCT04296175** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Fudan University** · enrollment: 808 (estimated)

## Conditions studied

- Triple-negative Breast Cancer

## Interventions

- **DRUG:** Epirubicin
- **DRUG:** CTX
- **DRUG:** Paclitaxel
- **DRUG:** ddEpirubicin
- **DRUG:** ddCTX
- **DRUG:** Paclitaxel(with carbo)
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT04296175
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-03-05
- **Primary completion:** 2025-03-10
- **Final completion:** 2027-03
- **Target enrollment:** 808 (ESTIMATED)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04296175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04296175, "Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04296175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*